Aspire Biopharma Holdings, Inc. - ASBP
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 12, 2026 | SCHEDULE 13G | Ardsley Advisory Partners LP | 7.76% | 10,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Ardsley Advisory Partners GP LLC | 7.76% | 10,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Ardsley Partners I GP LLC | 7.76% | 10,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Ardsley Partners Advanced Healthcare Fund, L.P. | 6.67% | 9,229,100 | View |
| Feb 12, 2026 | SCHEDULE 13G | Ardsley Partners Fund II, L.P. | 1.1% | 1,520,900 | View |
| Feb 12, 2026 | SCHEDULE 13G | Philip J. Hempleman | 7.76% | 10,750,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.